缬沙坦治疗心房颤动的效果及机制研究

Effect of valsartan on paroxysmal atrial fibrillation and its mechanism

目的:观察缬沙坦对心房颤动的治疗效果并探讨其作用机制。方法:选择无器质性心脏疾病的阵发性房颤(PAF)患者80例,均分为两组,缬沙坦组:使用缬沙坦口服治疗;对照组,不使用缬沙坦治疗,观察6个月。记录治疗前后两组房颤的发作频率及平均每次持续时间,并检测两组患者治疗前、后血浆基质金属蛋白酶9(MMP-9)的变化。结果:治疗6个月后,缬沙坦组患者房颤发作的频率[(7±2.3)次/周∶(11±3.6)次/周],平均持续时间[(102±31)min/次∶(131±44)min/次],MMP-9[(188.25±55.47)ng/ml∶(281.13±58.21)ng/ml]的含量均显著低于治疗前,也显著低于对照组[(14±6.7)次/周,(153±62)min/次,(261.72±52.94)ng/ml],P均<0.01。结论:缬沙坦治疗阵发性房颤有一定作用,而降低基质金属蛋白酶9的浓度可能是其治疗的机制之一。

Objective：To investigate the effect of valsartan on paroxysmal atrial fibrillation（PAF） and its mechanism.Methods：A total of 80 PAF and free from organic heart diseases patients were involved in the study.The patients were randomly average divided into two groups：valsartan group（in which patients were treated with valsartan）and control group（in which patients did not receive valsartan）.All patients were followed up for 6 month.The frequency of AF episode and mean time of onset of AF were recorded before and after treatment.Serum levels of matrix metalloproteinase-9（MMP-9） of the two groups were detected before and after treatment.Results：After 6 months,compared with before treatment the frequency of AF episode [（7±2.3） times /week vs.（11±3.6） times /week],mean time of onset of AF [（102±31）min/ time vs.（131±44） min/ time],MMP-9[（188.25±55.47）ng/ml vs.（281.13±58.21） ng/ml] significantly decreased in valsartan group,and also significantly decreased than those of control group [（14±6.7） times /week,（153±62） min/ time,（261.72±52.94） ng/ml],P0.01 all.Conclusion：Valsartan is effective for paroxysmal atrial fibrillation and decline of serum matrix metalloprotein-9 level may be one of its mechanisms.